Tepotinib

7 trials 4 recruiting LOncology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

6 Sponsors

9 Countries

Phase III

Phase II

Phase III: 1 Phase II: 6

Oversight events:

1 serious breach 2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Head and neck cancer 1

Sponsors using this IMP

Merck Healthcare KGaA 2 Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 HUS-Yhtymae 1 Intergroupe Francophone De Cancerologie Thoracique 1 Oslo University Hospital HF 1

All trials

7 total

Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in pa… Pending

2024-518892-72-00 Phase II 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting

2024-519971-25-00 Phase III 1 country Intergroupe Francophone De Cancerologie Thoracique
FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended

2024-512005-87-00 Phase II 5 countries Merck Healthcare KGaA
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended

2024-512003-39-00 Phase II 7 countries Merck Healthcare KGaA

Showing 1–7 of 7 trials

← All drugs A–Z